Literature DB >> 25689103

Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters.

Artem Vorobyev1, Hideyuki Ujiie2, Andreas Recke3, Jacqueline J A Buijsrogge4, Marcel F Jonkman4, Hendri H Pas4, Hiroaki Iwata3, Takashi Hashimoto5, Soo-Chan Kim6, Jong Hoon Kim6, Richard Groves7, Unni Samavedam3, Yask Gupta3, Enno Schmidt3, Detlef Zillikens3, Hiroshi Shimizu2, Ralf J Ludwig3.   

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease of the skin and mucous membranes, characterized by autoantibodies against type VII collagen (COL7), a major component of anchoring fibrils. Different clinical EBA phenotypes are described, including mechanobullous and inflammatory variants. Most EBA patients' sera react with epitopes located within the non-collagenous 1 (NC1) domain of human COL7. However, it has remained unclear whether antibody binding to these different epitopes is pathogenically relevant. To address this issue, we generated recombinant proteins covering the entire NC1 domain. IgG reactivity with these proteins was analyzed in sera of 69 EBA patients. Most recognized clusters of epitopes throughout the NC1 domain. No correlation was detected between antibody specificity and clinical phenotype. To study the pathogenicity of antibodies specific to different NC1 subdomains, rabbit antibodies were generated. All these antibodies caused dermal-epidermal separation ex vivo. Antibodies against two of these subdomains were injected into mice carrying null mutations of mouse COL7 and the human COL7 transgene and induced subepidermal blisters. We here document that autoantibodies to COL7, independent of the targeted epitopes, induce blisters both ex vivo and in vivo. In addition, using COL7-humanized mice, we provide in vivo evidence of pathogenicity of autoantibodies binding to human COL7.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25689103     DOI: 10.1038/jid.2015.51

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  56 in total

1.  Epidermolysis bullosa acquisita--a sign of cicatricial pemphigoid?

Authors:  M G Dahl
Journal:  Br J Dermatol       Date:  1979-10       Impact factor: 9.302

2.  Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice.

Authors:  Misa Hirose; Andreas Recke; Tina Beckmann; Atsushi Shimizu; Akira Ishiko; Katja Bieber; Jürgen Westermann; Detlef Zillikens; Enno Schmidt; Ralf J Ludwig
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

Review 3.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

4.  Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice.

Authors:  Cassian Sitaru; Mircea T Chiriac; Sidonia Mihai; Jürgen Büning; Andreas Gebert; Akira Ishiko; Detlef Zillikens
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

5.  Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid.

Authors:  Z Liu; L A Diaz; S J Swartz; J L Troy; J A Fairley; G J Giudice
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

6.  Cross-reactivity of autoantibodies from patients with epidermolysis bullosa acquisita with murine collagen VII.

Authors:  Kinga Csorba; Alina Sesarman; Eva Oswald; Vasile Feldrihan; Anja Fritsch; Takashi Hashimoto; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-01-20       Impact factor: 9.261

7.  Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa.

Authors:  J C Lapiere; D T Woodley; M G Parente; T Iwasaki; K C Wynn; A M Christiano; J Uitto
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

8.  Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients.

Authors:  David T Woodley; Ramin Ram; Arvin Doostan; Pubali Bandyopadhyay; Yi Huang; Jennifer Remington; Yingping Hou; Douglas R Keene; Zhi Liu; Mei Chen
Journal:  J Invest Dermatol       Date:  2006-06       Impact factor: 8.551

9.  Human type VII collagen: cDNA cloning and chromosomal mapping of the gene.

Authors:  M G Parente; L C Chung; J Ryynänen; D T Woodley; K C Wynn; E A Bauer; M G Mattei; M L Chu; J Uitto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Some epidermolysis bullosa acquisita sera react with epitopes within the triple-helical collagenous domain as indicated by immunoelectron microscopy.

Authors:  N Ishii; M Yoshida; A Ishida-Yamamoto; A Fritsch; S Elfert; L Bruckner-Tuderman; T Hashimoto
Journal:  Br J Dermatol       Date:  2009-11-25       Impact factor: 9.302

View more
  3 in total

1.  Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.

Authors:  Sung-Ah Hong; Song-Ee Kim; A-Young Lee; Gue-Ho Hwang; Jong Hoon Kim; Hiroaki Iwata; Soo-Chan Kim; Sangsu Bae; Sang Eun Lee
Journal:  Mol Ther       Date:  2022-06-10       Impact factor: 12.910

2.  Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Hiroshi Koga; Anika Kasprick; Rosa López; Mariona Aulí; Mercè Pont; Núria Godessart; Detlef Zillikens; Katja Bieber; Ralf J Ludwig; Cristina Balagué
Journal:  Front Immunol       Date:  2018-07-12       Impact factor: 7.561

Review 3.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.